Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 626 • 2019 ACR/ARP Annual Meeting
Are There Really Differences Between Non-radiographic and Radiographic Axial Spondyloarthritis? Data from the Spanish Atlas
Marco Garrido-Cumbrera¹, Jordi Gratacós ², Eduardo Collantes ³, Pedro Zarco ⁴, Carlos Sastre ⁵, Sergio Sanz-Gómez ⁶ and Victoria Navarro-Compán ⁷, ¹Health & Territory Research, Universidad de Sevilla, Seville, Spain, Sevilla, ²Hospital Universitari Parc Taulí, Sabadell, I3PT, UAB, Spain, Sabadell, Spain, ³Reina Sofia University Hospital, Spain. Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba, Cordova, Spain, Cordova, Spain, ⁴Hospital Universitario Fundación Alcorcón, Madrid, Spain, Madrid, Spain, ⁵Novartis Spain, Barcelona, Spain, Barcelona, Spain, ⁶Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, Seville, Spain, ⁷University Hospital La Paz, IdiPaz, Madrid, Spain
Background/Purpose: Most research studies support the fact that both, radiographic and non-radiographic axial spondyloarthritis (r-axSpA and nr-axSpA), share similar clinical characteristics and equivalent burden of…
Abstract Number: 1519 • 2019 ACR/ARP Annual Meeting
Predicting Response to Biologic Therapy in Patients with Axial Spondyloarthritis (axSpA)
Gareth Jones¹, Linda Dean ¹, Ejaz Pathan ² and Gary Macfarlane ¹, ¹University of Aberdeen, Aberdeen, United Kingdom, ²Toronto Western Hospital, Toronto, Canada
Background/Purpose: In axial spondyloarthritis (axSpA), the clinical benefits of TNF inhibition (TNFi) are well documented although, by design, most studies report average benefits in groups…
Abstract Number: 2774 • 2019 ACR/ARP Annual Meeting
Cluster-based Spondyloarthritis Phenotypes Defined at Baseline Are Predictive of Different Severity Outcomes at 5-Year in the DESIR Cohort
Félicie Costantino ¹, Philippe Aegerter ², Anna Moltó ³, Georg Schett ⁴, Maxime Breban ⁵ and Maria-Antonietta D'Agostino⁶, ¹UMR1173, INSERM/Versailles-Saint Quentin University, France Ambroise Paré Hospital (AP-HP) Department of Rheumatology, Boulogne-Billancourt, France, Boulogne Billancourt, France, ²Public Health Department - GIRCI IdF - INSERM/Versailles-Saint Quentin University, France, Versailles, France, ³Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, ⁴Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, ⁵UMR1173, INSERM/Versailles-Saint Quentin University, France Ambroise Paré Hospital (AP-HP) Department of Rheumatology, Boulogne-Billancourt, France, Boulogne Billancourt, ⁶UMR1173, INSERM/Versailles-Saint Quentin University, France Ambroise Paré Hospital (AP-HP) Department of Rheumatology, Boulogne Billancourt, France
Background/Purpose: The course of axial spondyloarthritis (SpA) is heterogeneous and remains to be better defined. DESIR is a longitudinal French cohort of early undifferentiated axial…
Abstract Number: 585 • 2019 ACR/ARP Annual Meeting
Effect of Testosterone on Spinal Ankylosis in Ankylosing Spondylitis : in Vivo and in Vitro
Sungsin Jo¹, Eun-Ju Lee ², Juyeon Kang ¹, Seunghun Lee ³, Jeehee Youn ⁴, Yong-Gil Kim ⁵ and Tae-Hwan Kim ¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ²Ulsan university, seoul, Republic of Korea, ³Dertment of Radiology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁴Hanyang University, seoul, Republic of Korea, ⁵Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: Ankylosing spondylitis (AS) is a predominantly male disease and spinal ankylosis more severely affect male AS1 suggesting role of testosterone on spinal ankylosis. In…
Abstract Number: 628 • 2019 ACR/ARP Annual Meeting
Pain Perception and Opiate Use Among Patients with Inflammatory Arthritis
Alexis Ogdie¹, Sofia Pedro ² and Kaleb Michaud ³, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS
Background/Purpose: Pain is the most common symptom among patients with inflammatory arthritis (IA) and residual pain is common in patients IA despite appropriate treatment. Opiate…
Abstract Number: 1521 • 2019 ACR/ARP Annual Meeting
Ixekizumab Is Effective in the Treatment of Radiographic Axial Spondyloarthritis Regardless of the Level of C-Reactive Protein or Magnetic Resonance Imaging Scores
Walter P. Maksymowych¹, Gaia Gallo ², Rebecca Bolce ³, Fangyi Zhao ², Vladimir Geneus ³, Mikkel Østergaard ⁴, Kurisu Tada ⁵, Atul Deodhar ⁶ and Lianne Gensler ⁷, ¹University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ²Eli Lilly and Company, Indianapolis, IN, ³Eli Lilly and Company, Indianapolis, ⁴Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ⁵Juntendo University School of Medicine, Tokyo, Japan, ⁶Oregon Health & Science University, Portland, OR, ⁷University San Francisco California, San Francisco, CA
Background/Purpose: IL-17 plays an important role in the pathogenesis of radiographic axial spondyloarthritis (r-axSpA). Elevated CRP levels in serum predict response to TNF inhibitors (TNFi).1-4…
Abstract Number: 2852 • 2019 ACR/ARP Annual Meeting
Shared and Differing Risk Factors for PsA, Psoriasis, AS, and RA: A Series of Case-control Studies
Alexis Ogdie¹, Xingmei Wang ¹, Thorvardur J Love ², Telma Thrastardottir ³, Maureen Dubreuil ⁴ and Joel Gelfand ⁵, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ³University of Iceland, Reykjavik, Iceland, ⁴Boston University School of Medicine, Boston, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: While a handful of clinical risk factors for the development of inflammatory diseases have been identified, to date, no studies have compared risk factors…
Abstract Number: 587 • 2019 ACR/ARP Annual Meeting
Increased Prevalence of Cardiac Disorders in Dutch Ankylosing Spondylitis Patients: The CARDAS Study
Milad Baniaamam¹, Sjoerd Heslinga ², Thelma Konings ³, Otto Kamp ³, Vokko van Halm ³, Irene van der Horst-Bruinsma ² and Mike Nurmohamed ⁴, ¹Amsterdam Rheumatology and immunology Center, Rheumatology, Reade, Amsterdam|Amsterdam Rheumatology and immunology Center, Rheumatology, Amsterdam University Medical Center location VUmc, Amsterdam, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center, Rheumatology, Amsterdam University Medical Center location VUmc, Amsterdam, Amsterdam, Netherlands, ³Amsterdam University Medical Center, location VUmc, Department of Cardiology, Amsterdam, Amsterdam, Netherlands, ⁴Amsterdam Rheumatology and immunology Center location Reade and Amsterdam UMC location VU medical center, Amsterdam, Netherlands
Background/Purpose: The overall mortality rate in ankylosing spondylitis (AS) patients is increased by 60–90% compared with the general population. This higher mortality rate is predominately…
Abstract Number: 631 • 2019 ACR/ARP Annual Meeting
Recognition of Inflammatory Back Pain by US Healthcare Providers and Barriers to Specialist Referral
Marina Magrey¹, Esther Yi ², Daniel Wolin ³, Mark Price ³, Costel Chirila ³, Eric Davenport ³ and Yujin Park ⁴, ¹Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³RTI Health Solutions, Research Triangle Park, ⁴Novartis Pharmaceuticals Corporation, East Hanover
Background/Purpose: Early diagnosis of axial spondyloarthritis (axSpA) in the United States remains challenging due to the high prevalence and nonspecific presentation of chronic back pain…
Abstract Number: 1529 • 2019 ACR/ARP Annual Meeting
The Efficacy and Safety of Anti-TNFα Treatment in Ankylosing Spondylitis Patients with Late Onset Compared to Those with Adult Onset; The Data from TURKBIO Registry
Sadettin Uslu¹, Gercek Can ², Ayşe Cefle ³, Sema Yılmaz ⁴, Sinem Burcu Kocaer ⁵, Tuba Yüce İnel ¹, Semih Gülle ¹, Süleyman Serdar Koca ⁶, Servet Yolbaş ⁷, Mehmet Akif Öztürk ⁸, Soner Senel ⁹, Nevsun Inanc ¹⁰, Ediz Dalkılıç ¹¹, Ozgül Gunduz ¹², Abdurrahman Tufan ⁸, Servet Akar ¹³, Merih Birlik ⁵, Ismail Sari ¹, Nurullah Akkoç ¹² and Fatos Onen ¹⁴, ¹Division of Rheumatology, Dokuz Eylül University School of Medicine, İzmir, Turkey, Izmir, Turkey, ²Dokuz Eylul University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Izmir, Turkey, ³Division of Rheumatology, Kocaeli University School of Medicine, Kocaeli, Turkey, Kocaeli, Turkey, ⁴Division of Rheumatology, Selcuk University School of Medicine, Konya, Turkey, Konya, Turkey, ⁵Division of Rheumatology, Dokuz Eylül University School of Medicine, İzmir, Turkey, Turkey,Izmir, Izmir, Turkey, ⁶Fırat University School of Medicine Division of Rheumatology, Elazığ, Turkey, ⁷Division of Rheumatology, Inonu University School of Medicine, Malatya, Turkey, Malatya, Turkey, ⁸Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey, Ankara, Turkey, ⁹Division of Rheumatology, Erciyes University School of Medicine, Kayseri, Turkey, Kayseri, Turkey, ¹⁰Marmara University, Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ISTANBUL, Turkey, ¹¹Uludağ University, Bursa, Turkey, ¹²Division of Rheumatology, Celal Bayar University School of Medicine, Manisa, Turkey, Manisa, Turkey, ¹³Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, ¹⁴Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey
Background/Purpose: The first symptoms of ankylosing spondylitis (AS) patients usually begin prior to 45 years, but can occur later in life. The purpose of this…
Abstract Number: 588 • 2019 ACR/ARP Annual Meeting
The Gut Enthesis Axis Coming into Focus with the Description of Enriched Entheseal Resident Mucosal Associated Invariant T-cells (MAITs) Capable of IL17A and TNF Production
Richard Cuthbert ¹, Qiao Zhou ², Abdulla Watad ³, Robert Dunsmuir ⁴, Peter Loughenbury ⁴, Almas Khan ⁴, Peter Milner ⁴, Charles Bridgewood ⁵ and Dennis McGonagle², ¹University of Leeds, Leeds, ²University of Leeds, Leeds, United Kingdom, ³Department of Medicine “B”, Zabludowicz Center for Autoimmune Diseases Sheba Medical Center, Ramat-Gan, Israel, ⁴Leeds Teaching Hospitals NHS Trust, Leeds, ⁵Leeds Institute of Rheumatic and Muscoskeletal Medicine(LIRMM), University of Leeds, Leeds, United Kingdom
Background/Purpose: Mucosal associated invariant T-cells (MAITs) are innate-like T lymphocytes that express a semi-invariant TCR repertoire that are activated by microbial ligands or cytokines including…
Abstract Number: 933 • 2019 ACR/ARP Annual Meeting
Tumor Necrosis Factor Inhibitors Slow Radiologic Progression in Patients with Ankylosing Spondylitis: 18-year Longitudinal Cohort Study
Bon San Koo¹, Ji Seon Oh ², Seo Young Park ³, Ga Young Ahn ⁴, Seunghun Lee ⁵, Kyung Bin Joo ⁶ and Tae-Hwan Kim ⁷, ¹Department of Internal Medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea, ²Department of Biomedical Informatics, Asan Medical Center, Seoul, Korea, Seoul, Republic of Korea, ³Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Seoul-t'ukpyolsi, Republic of Korea, ⁴Korea University Guro Hospital, Seoul, Republic of Korea, ⁵Dertment of Radiology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁶Department of Radiology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Seoul-t'ukpyolsi, Republic of Korea, ⁷Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
Background/Purpose: It is difficult to evaluate the role of TNF inhibitor therapy in slowing the radiologic progression in patients with ankylosing spondylitis (AS) because of…
Abstract Number: 1530 • 2019 ACR/ARP Annual Meeting
Real World Effectiveness of Secukinumab in Patients with Ankylosing Spondylitis: Findings from a Recent Cross Sectional Survey of Rheumatologists and Patients in Europe
Uta Kiltz ¹, Elizabeth Holdsworth², Haijun Tian ³, Nicola Booth ⁴, Papa Anthony ⁵, Lina Helsche ⁶, Dorothy Keininger ⁶ and Philip G Conaghan ⁷, ¹Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ²Adelphi Real World, Manchester, England, United Kingdom, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Adelphi Real World, Macclesfield, England, United Kingdom, ⁶Novartis Pharma AG, Basel, Basel-Landschaft, Switzerland, ⁷Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: Ankylosing spondylitis (AS) can lead to reduced physical functioning and quality of life. Secukinumab has demonstrated clinical benefits in AS patients in clinical trials1-2.…
Abstract Number: 596 • 2019 ACR/ARP Annual Meeting
Prostaglandin Receptor EP4 Drives Pathogenic Th17 Cell Development in Ankylosing Spondylitis and Is a New Marker of Disease Activity
Anja Meyer¹, Charlotte Klasen ¹, Pauline Wittekind ¹, Iris Waqué ¹, Schafiq Nabhani ¹ and David Kofler ¹, ¹University of Cologne, Cologne, Germany
Background/Purpose: Th17 cells are involved in the pathogenesis of ankylosing spondylitis (AS). However, the mechanism underlying enhanced Th17 cell accumulation in AS remains unknown. The…
Abstract Number: 937 • 2019 ACR/ARP Annual Meeting
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Ankylosing Spondylitis: 48-Week Efficacy and Safety Results from a Phase 2b, Randomized, Blinded, Placebo-Controlled, Dose-Ranging Study
Désirée van der Heijde¹, Lianne Gensler ², Atul Deodhar ³, Xenofon Baraliakos ⁴, Denis Poddubnyy ⁵, Alan Kivitz ⁶, Marga Oortgiesen ⁷, Dominique Baeten ⁸, Nadine Goldammer ⁹, Jason Coarse ⁷, MK Farmer ⁷ and Maxime Dougados ¹⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²University San Francisco California, San Francisco, CA, ³Oregon Health & Science University, Portland, OR, ⁴Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁵Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ⁸UCB Pharma, Brussels, Belgium, Brussels, ⁹UCB Pharma, Monheim, Germany, Monheim, Germany, ¹⁰Cochin Hospital, Paris, France
Background/Purpose: The monoclonal antibody bimekizumab potently and selectively neutralizes both IL-17A and IL-17F. We report the 48-week efficacy and safety of bimekizumab in patients (pts)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].